Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- German Authority Confirms Additional Benefit of Lenvatinib in RCC
March 29, 2017
- Mochida Gets Japan Distribution Rights to Tyvaso
March 29, 2017
- Shionogi Seeks to Expand Pediatric Use for Allergen Immunotherapy Actair
March 29, 2017
- Astellas Unloading 16 Off-Patent Brands to LTL Pharma
March 29, 2017
- Mitsubishi Tanabe to Pull Plug on Generics, Transfer Biz to Nipro in October
March 29, 2017
- Ono Clinches Immuno-Oncology Drug Discovery Deal with Numab
March 29, 2017
- AZ Japan to Introduce Business Unit Structure in April
March 28, 2017
- Tivantinib Fails Japan PIII Trial for HCC: Kyowa Kirin
March 28, 2017
- Nippon Shinyaku Gets Exclusive Japan Rights to Novel AML Drug
March 27, 2017
- Chugai Notches Supreme Court Victory in Oxarol Patent Suit
March 27, 2017
- AZ Gets Asian Rights to Kyowa Kirin’s Benralizumab
March 27, 2017
- Nobelpharma to Copromote Nobelzin with ASKA, Medipal upon Hypozincemia Nod
March 27, 2017
- EMA Accepts Schizophrenia Med Brexpiprazole for Review: Otsuka/Lundbeck
March 27, 2017
- Torii Seeks Pediatric Indication for Allergen Immunotherapy Miticure
March 27, 2017
- Shionogi Gets FDA Nod for Naldemedine
March 27, 2017
- Hit Compounds Enter POC Evaluation Stage in DNDi’s NTD Drug Discovery Booster Project
March 27, 2017
- Alexion Files Soliris for Refractory gMG
March 24, 2017
- Takata, Meiji Settle Patent Suit with Toyama Chemical over Pediatric Ozex Drug
March 24, 2017
- Wholesale Dealer President Deeply Sorry for Letting Fake Harvoni into Supply Chain
March 24, 2017
- Koshiya Tapped as Global Head of Oncology: Sumitomo Dainippon
March 23, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…